J Louise Jones

List of Publications by Year in descending order

33 papers	2,388 citations	304743 22 h-index	434195 31 g-index
33 all docs	33 docs citations	33 times ranked	3904 citing authors

#	Article	IF	Citations
1	Jekyll and Hyde: the role of the microenvironment on the progression of cancer. Journal of Pathology, 2011, 223, 163-177.	4.5	309
2	Rigidity sensing and adaptation through regulation of integrin types. Nature Materials, 2014, 13, 631-637.	27.5	304
3	Alteration of stromal protein and integrin expression in breastâ€”a marker of premalignant change?. Journal of Pathology, 1992, 167, 399-406.	4.5	184
4	Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion. Cancer Research, 2008, 68, 2755-2763.	0.9	172
5	Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. , 1999, 189, 161-168.		166
6	The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Research, 2015, 17, 52.	5.0	146
7	Hard X-ray dark-field imaging with incoherent sample illumination. Applied Physics Letters, 2014, 104, .	3.3	145
8	Therapeutic Targeting of Integrin Î±vÎ²6 in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	132
9	Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Research, 2009, 11, R24.	5.0	101
10	Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of Î±vÎ²6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence. Clinical Cancer Research, 2014, 20, 344-357.	7.0	77
11	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. Current Biology, 2016, 26, 755-765.	3.9	57
12	Overdiagnosis and overtreatment of breast cancer: Progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Research, 2006, 8, 204.	5.0	55
13	Molecular pathology of breast cancer and its application to clinical management. Cancer and Metastasis Reviews, 1997, 16, 5-27.	5.9	53
14	Cancer Burden Is Controlled by Mural Cell-Î²3-Integrin Regulated Crosstalk with Tumor Cells. Cell, 2020, 181, 1346-1363.e21.	28.9	53
15	An immunohistochemical andin situ hybridization study ofc-myc andc-erbB-2 expression in primary human breast carcinomas. Journal of Pathology, 1989, 158, 97-105.	4.5	51
16	Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells. Developmental Cell, 2020, 55, 298-313.e10.	7.0	50
17	Breast implantâ€associated anaplastic large cell lymphoma (BIAâ€ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. Histopathology, 2019, 75, 787-796.	2.9	45
18	PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. Cell Reports, 2018, 22, 2469-2481.	6.4	34

#	Article	IF	Citations
19	Clinical and functional significance of Î±9Î²1 integrin expression in breast cancer: a novel cellâ€surface marker of the basal phenotype that promotes tumour cell invasion. Journal of Pathology, 2011, 223, 646-658.	4.5	33
20	Î±vÎ²6 Expression in Myoepithelial Cells: A Novel Marker for Predicting DCIS Progression with Therapeutic Potential. Cancer Research, 2014, 74, 5942-5947.	0.9	32
21	A 3D in vitro model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer. Breast Cancer Research, 2017, 19, 50.	5.0	31
22	Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Breast Cancer Research, 2017, 19, 33.	5.0	29
23	GATA3 Mutations Found in Breast Cancers May Be Associated with Aberrant Nuclear Localization, Reduced Transactivation and Cell Invasiveness. Hormones and Cancer, 2013, 4, 123-139.	4.9	28
24	Time for change: a new training programme for morpho-molecular pathologists?. Journal of Clinical Pathology, 2018, 71, 285-290.	2.0	21
25	Stromal characteristics may hold the key to mammographic density: the evidence to date. Oncotarget, 2016, 7, 31550-31562.	1.8	20
26	Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial. Clinical Cancer Research, 2021, 27, 5317-5324.	7.0	17
27	Morphomolecular pathology: setting the framework for a new generation of pathologists. British Journal of Cancer, 2017, 117, 1581-1582.	6.4	16
28	Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial. Clinical Cancer Research, 2021, 27, 2861-2867.	7.0	9
29	Derivation of a nuclear heterogeneity image index to grade DCIS. Computational and Structural Biotechnology Journal, 2020, 18, 4063-4070.	4.1	8
30	The assessment ofin vitro modulation of milk fat globule membrane expression by human breast carcinomas. Journal of Pathology, 1987, 153, 51-60.	4.5	4
31	Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence. Pathobiology, 2023, 90, 31-43.	3.8	4
32	In vitro modulation of cellular localization of milk fat globule membrane antigens in human breast carcinomas. Journal of Pathology, 1991, 164, 127-133.	4.5	2
33	Development of a Validated Exam to Assess Pathologist Knowledge of Genomic Oncology. Archives of Pathology and Laboratory Medicine, 2021, 145, 453-456.	2.5	0